Anti-CD20 (Ofatumumab biosimilar - IgG1 isotype)
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-hCD20-Of-hIgG1 Human CD20 (Ofatumumab) antibody - Human IgG1 |
Show product |
100 µg 1 mg |
hcd20of-mab1
|
|
Human IgG1 monoclonal antibody (mAb) against human CD20
Anti-hCD20-Of-hIgG1 is the biosimilar of the clinical antibody ofatumumab. Anti-hCD20-Of-hIgG1 features the constant region (Fc) of a human IgG1 isotype and the variable region of ofatumumab. Ofatumumab targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.
Ofatumumab is a fully human type I (first generation) monoclonal antibody that mediates B cell destruction through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Ofatumumab has been approved by the FDA to treat chronic lymphocytic leukemia (CLL) [1-3].
InvivoGen’s Anti-hCD20-Of-hIgG1 is generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used to compare several biological activities such as ADCC (see below or in the 'upon request' section).
InvivoGen also provides type I and type II anti-hCD20 mAbs featuring the variable regions of Rituximab or Obinutuzumab, with either native or engineered Fc region.
Read our review on Antibody Isotypes
References:
1. Baig NA. et al., 2014. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol. 192(4):1620-9.
2. Lin TS., 2010. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 3:51-9.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.
Specifications
Target: Human CD20
Clonality: Monoclonal antibody
Clone: Ofatumumab (Anti-hCD20-hIgG1, kappa)
Isotype: Human IgG1, kappa
Control: Human IgG1
Source: CHO cells
Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose and stabilizing agents
Purity: Purified by affinity chromatography with protein G
Tested application: Flow cytometry
Quality control:
- Binding of Anti-hCD20-Of-hIgG1 to human CD20 has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Contents
Anti-hCD20-Of-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hcd20of-mab1: 100 µg
- hcd20of-mab1-1: 1 mg
Anti-hCD20-Of-hIgG1 is shipped at room temperature.
Upon receipt, store lyophilized antibody at -20 °C.
Tags: buy Ofatumumab (Anti-CD20) | Ofatumumab (Anti-CD20) supplier | purchase Ofatumumab (Anti-CD20) | Ofatumumab (Anti-CD20) cost | Ofatumumab (Anti-CD20) manufacturer | order Ofatumumab (Anti-CD20) | Ofatumumab (Anti-CD20) distributor
Back to the top